louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06009419: Effectiveness of Dual Task Training in Total Hip Arthroplasty
Official title: Effectiveness of Dual Task Training Versus Usual Care in Patients With Total Hip Arthroplasty: A Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Hip Arthroplasty
Lead sponsor: Muğla Sıtkı Koçman University
Sponsor class: OTHER
First posted: 2023-08-24
Enrollment: 28
Sex: ALL
Minimum age (years): 60
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study was planned to investigate the effectiveness of usual care and dual task program in patients who underwent total hip arthroplasty surgery. It is aimed to evaluate pain intensity, disability level, mini mental status, coordination, balance and functional status of the patients. The study will be conducted with volunteer patients who are followed up by the Orthopedics and Traumatology outpatient clinic of Muğla Training and Research Hospital and who have undergone total hip arthroplasty surgery. The evaluations will be performed in the Orthopedics and Traumatology outpatient clinic of Muğla Training and Research Hospital. It is aimed to evaluate at least 24 patients for the study.


Eligibility criteria: Inclusion Criteria:

* Having undergone unilateral total hip arthroplasty surgery and being 6 weeks postoperative
* Participate in all necessary follow-up assessments
* 60 years of age or older
* Understand simple commands
* Signing the consent form

Exclusion Criteria:

* A previous history of total hip arthroplasty
* Presence of revision surgery
* Presence of severe osteoarthritis in the contralateral hip
* Severe acute metabolic neuromuscular and cardiovascular diseases
* Severe obesity (bki\>35)
* Presence of malignancy
* Have any other orthopedic or neurological problem that may affect treatment and assessments
* Situations that prevent communication
* Lack of cooperation during the study

Primary outcomes:
measure: Five Times Sit to Stand Test (5TSST)
timeFrame: Change from Baseline 5TSST at 8 weeks
measure: Cognitive Timed Up and Go Test (CTUG)
timeFrame: Change from Baseline CTUG at 8 weeks
measure: Dual-Task Questionnaire (DTQ)
timeFrame: Change from Baseline DTQ at 8 weeks
measure: Activity Specific Balance Confidence Scale (ABC)
timeFrame: Change from Baseline ABC at 8 weeks
measure: Visual Analog Scale (VAS)
timeFrame: Change from Baseline VAS at 8 weeks
measure: Harris Hip Score (HHS)
timeFrame: Change from Baseline HHS at 8 weeks
measure: Mini-Mental State Examination (MMSE)
timeFrame: Change from Baseline MMSE at 8 weeks
measure: Lower-Extremity Motor Coordination Test (LEMOCOT)
timeFrame: Change from Baseline LEMOCOT at 8 weeks
measure: 4-Meter Gait Speed (4MGS)
timeFrame: Change from Baseline 4MGS at 8 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Muğla
country: Turkey
facility: Muğla Sıtkı Koçman Training and Research Hospital
state: Menteşe
Study officials:
affiliation: Muğla Sıtkı Koçman University
name: Fatih Özden, PhD
role: STUDY_DIRECTOR
References:
Clinical trial NCT04363619: Insights From the Retina on Cerebral Microvascular Dysfunction in Haemorrhagic Stroke
Official title: Insights From the Retina on Cerebral Microvascular Dysfunction in Haemorrhagic Stroke. A Prospective Observational Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Intracerebral Hemorrhage
Lead sponsor: University of Zurich
Sponsor class: OTHER
First posted: 2020-04-27
Enrollment: 14
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: Fundoscopy, optical coherence tomography (OCT) and OCT-angiography (OCTA) are established examinations and bear minimal risks. The recognition of retinal microvascular signs will enhance the pathophysiological understanding of the vasculopathy in patients with intracerebral haemorrhage (ICH) and aneurysmatic subarachnoid hemorrhage (aSAH) and might serve as prognostic and diagnostic indicators.

Detailed description: The purpose of the study is to

* To evaluate the feasibility of fundoscopy, OCT and OCTA imaging in the environment of a Neurocritical Care Unit (NCCU)
* To detect, quantify and associate microvascular changes in the retina with signs of micro-vessel disease in ICH and DCI in aSAH

Eligibility criteria: Inclusion Criteria:

* All groups

  * Primary ICH or aSAH with symptoms onset \< 3 days
  * 18 to unlimited years of age
  * Signed informed consent obtained from legal representative or patient ICH group
  * Primary ICH localized either in basal ganglia, thalamus, pons or cerebellum aSAH group
  * Ruptured aneurysm visualized in contrast-enhanced computed tomography (angio-CT), MRI or cerebral angiography Control group
  * Stroke due to perimesencepahlic subarachnoid hemorrhage, arteriovenous malformation or isolated traumatic brain injury

Exclusion Criteria:

* All groups

  * Cerebral amyloid angiopathy or other neurodegenerative disease
  * History of migraine with aura or ischemic stroke
  * Contraindication for pupil dilation (intracranial hypertension, allergy against mydriatics, angle closure glaucoma)
  * Any pre-existing or manifest ocular condition affecting either the integrity of retinal vessels, transparency of optical media or the risk of acute angle closure glaucoma
  * Concomitant instable critical illness (e.g. sepsis, multi-organ failure)
  * Intracranial pressure \> 20mmHg and refractory to cerebrospinal fluid drainage
  * Pregnancy

Primary outcomes:
measure: i. Number of fundus photography, OCT, and OCTA examinations with usable and quantifiable results.
timeFrame: From hospital entry up to 3-6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Zurich
country: Switzerland
facility: University Hospital Zurich
Study officials:
References:
Clinical trial NCT01312519: Powered Bone Marrow Aspiration and Core Biopsy System Compared to Manual Devices
Official title: A Trial of the Vidacare Powered Bone Marrow Aspiration and Core Biopsy Systems (OnControl by Vidacare) Compared to Traditional Manual Devices
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Bone Marrow Biopsy Procedures
Keywords: Bone marrow biopsy of iliac crest
Lead sponsor: Vidacare Corporation
Sponsor class: INDUSTRY
First posted: 2011-03-10
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: This is a randomized study evaluating use of a powered bone marrow biopsy and aspiration system (OnControl by Vidacare) compared to traditional manual devices. The hypothesis is that the powered system will reduce the level of patient pain during the aspiration and core biopsy procedures and the amount of time needed to perform the procedures.


Eligibility criteria: Inclusion Criteria:

* Adults over the age of 18
* Patients that require core biopsy alone, or core biopsy and bone marrow aspiration

Exclusion Criteria:

* Imprisoned
* Pregnant
* Cognitively impaired
* Requiring english language translation other than Spanish
* Patients with one or more conditions precluding bone marrow core biopsy

Primary outcomes:
measure: Subject Reported Level of Pain During Procedure
timeFrame: Day 1 during the needle insertion
Secondary outcomes:
measure: Time Necessary to Perform the Bone Marrow Procedure
timeFrame: Day 1 needle insertion through needle removal
Other outcomes:
Locations:
city: San Antonio
country: United States
facility: Cancer Therapy and Research Center
state: Texas
city: Madrid
country: Spain
facility: Hospital General Universitario Gregorio Maranon
Study officials:
affiliation: Vidacare Corporation
name: Thomas Philbeck, PhD
role: STUDY_DIRECTOR
References:
Clinical trial NCT04905719: Point-of-Care Ultrasound in Primary Care
Official title: Reliability of Point-of-Care Ultrasound Examination in Primary Care Performed by a General Practitioner
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Ultrasound
Lead sponsor: Emergency Medical Service of the Central Bohemian Region, Czech Republic
Sponsor class: OTHER
Collaborators: name: The Society of General Practice, J. E. Purkyne Czech Medical Association
name: Institute for Postgraduate Medical Education, Czech republic
First posted: 2021-05-28
Enrollment: 600
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Adult outpatients.

Brief summary: The purpose of this study is to evaluate reliability of Point-of-Care ultrasound evaluation performed by general practitioners.

Detailed description: The purpose of this study is to evaluate reliability of Point-of-Care ultrasound (POCUS) evaluation performed by general practitioners.

General practitioners who underwent predefined training in POCUS will perform ultrasound examination in outpatients meeting inclusion criteria. While this is observational study, result will not have an impact on the management of the patients.

Regardless of the POCUS examination, patients undergo a routine diagnostic process which is appropriate for the initial symptom. Imaging examinations will always be a part of this. This will serve as an expert control to evaluate the reliability of POCUS Each POCUS examination will also be recorded as a video loop, subsequently assessed by an expert in the POCUS and also used as an expert control.

The data will be analyzed by standard reliability testing.

Eligibility criteria: Inclusion Criteria:

* Patient with abdominal pain in the right upper quadrant (will be indicated for the abdominal ultrasound) or patient with dyspnoea (will be indicated for lung ultrasound) or patient with suspected deep vein thrombosis (will be indicated for compression ultrasound testing)
* Signing of informed consent to participate in the study

Exclusion Criteria:

* Age \<18 years
* Refusal of ultrasound examination by patient
* Any circumstance that prevents ultrasonographic examination (eg allergy to ultrasonographic gel, skin lesions that do not allow safe examination, etc.)

Primary outcomes:
measure: Reliability of Point-of-Care ultrasound investigation of the lungs, gall bladder or proximal deep veins of lower extremities performed by general practitioner compared with the expert diagnostic method
timeFrame: 7 months
Secondary outcomes:
Other outcomes:
Locations:
city: Usti nad Labem
country: Czechia
facility: Masaryk Hospital Usti nad Labem
Study officials:
affiliation: Masaryk Hospital Usti nad Labem
name: Roman Skulec, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02681419: Evaluating the Efficacy of Fenestrations in Tube Shunt Implants During the Early Postoperative Period
Official title: Evaluating the Efficacy of Fenestrations in Tube Shunt Implants During the Early Postoperative Period
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE4
Conditions: Glaucoma
Lead sponsor: The University of Texas Health Science Center, Houston
Sponsor class: OTHER
Collaborators: name: Robert Cizik Eye Clinic
First posted: 2016-02-12
Enrollment: 18
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study evaluates two different methods of controlling intraocular pressure in nonvalved aqueous tube shunts immediately after implantation; needle fenestrations or a suture wick.

Detailed description: This is a prospective, randomized control study of glaucomatous eye undergoing tube shunt implantation using a nonvalved implant for poorly controlled glaucoma of any type. Eyes scheduled to receive a nonvalved tube shunt implant will be randomized to receive either needle fenestration(s) or a suture wick using a single 10-0 vicryl anterior to the ligature. The operative quadrant will be imaged using anterior-segment optical coherence tomography at pre- and post-operative visits.

Eligibility criteria: Inclusion Criteria:

* 18 years of age or older
* Eyes that have poorly controlled glaucoma requiring a tube shunt implantation
* Willingness to participate in the study and sign informed consent

Exclusion Criteria:

* Concurrent surgery except phaco/intraocular lens
* Any abnormality preventing reliable applanation tonometry
* Eyes with exposure limitation (tight lids, deep orbits) that would make performing the anterior segment optical coherence tomography difficult

Primary outcomes:
measure: Number of participants with successful control of intraocular pressure
timeFrame: 3 weeks
Secondary outcomes:
measure: Duration of effect on intraocular pressure control
timeFrame: 12 weeks
measure: Peri-fenestration bleb volume prior to tube opening
timeFrame: 3 weeks
measure: Peri-fenestration bleb volume after the tube has opened
timeFrame: 12 weeks
measure: Intraocular pressure after the tube has opened
timeFrame: 12 weeks
Other outcomes:
Locations:
city: Houston
country: United States
facility: Robert Cizik Eye Clinic
state: Texas
Study officials:
affiliation: Robert Cizik Eye Clinic
name: Lauren S. Blieden, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00749619: Addition of Heparin to Taurolock-TM CLS in HD Patients With TCC Dose it Improve Catheter Patency Problems ?
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: End Stage Renal Disease
Hemodialysis
Keywords: Tunneled Cuffed Catheter
Catheter Lock Solution
Catheter Related Bacteremia
Lead sponsor: Western Galilee Hospital-Nahariya
Sponsor class: OTHER_GOV
First posted: 2008-09-09
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Primary purpose: PREVENTION

Brief summary: Addition of Heparin to the Catheter Lock Solution (CLS): Taurolock-TM will improve the vascular patency compared to Taurolock-TM alone , in hemodialysis patients with Tunneled Cuffed Catheter(TCC) as vascular access.

Detailed description: Bacteremia and thrombosis are the major complications of TCC used for hemodialysis.Instilation of CLS containing antibiotic-anticoagulant solution in the end of each dialysis session till the next dialysis ,can prevent Catheter related bacteremia (CRB).In previous study in our department, Taurolock-TM decreased the rate of CRB but increased the incidence of catheter malfunction.

The aim of the study is to investigate the influence of of Heparin addition to CLS-Taurolock- TM ( Taurolidine \&citrate 4%) in prevention of catheter patency problems in HD patients with TCC, in addition to CRB prevention.

Methods : Patients with newly inserted TCC for HD enrolled and randomized to receive one of three CLS types : group 1- Taurolock-TM, Group 2 - Taurolock-TM and Heparin , Group 3- Heparin .Patients were followed for 6 monthes.

The objective of the study is to investigate the effect of Taurolock TM with heparin on the rate of CRB and vascular patency.

Eligibility criteria: Inclusion Criteria:

* Hemodialysis patients with new TCC
* Informed Consent

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Nahariya
country: Israel
facility: Western Galilee Hospital
Study officials:
References:
Clinical trial NCT01528319: Open-Label Study for Shoulder Dislocation Using MG-1
Official title: Open Clinical Trial of Arthroscopic Bankart Repair Using MG-1 for Dislocation of the Shoulder
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Shoulder Dislocation
Keywords: Arthroscopic Bankart repair
Suture anchor
Shoulder dislocation
Lead sponsor: Johnson & Johnson K.K. Medical Company
Sponsor class: INDUSTRY
First posted: 2012-02-08
Enrollment: 24
Sex: ALL
Minimum age (years): 16
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: To evaluate the efficacy and safety of arthroscopic Bankart repair using MG-1 for dislocation of shoulder


Eligibility criteria: Inclusion Criteria:

* Patients with dislocation of the shoulder and indicated for arthroscopic Bankart repair
* Patients of 16 years or older
* Patients who understand the contents of the study and from whom a written consent can be obtained
* Patients who can visit the hospital for follow-ups after surgery

Exclusion Criteria:

* Patients with serious complications
* Patients with comminuted fracture which may prevent fixation of the anchors
* Patients with the following diseases or conditions which may delay healing

  1. Lack of blood, infection, etc.
  2. Psychiatric disorder, alcohol poisoning, drug toxicity, etc.
  3. Tissues around the surgical site are not healthy under steroid therapy or chemotherapy
* Patients with epilepsy or bone disease (cystic change, osteopenia, etc.)
* Patients with dementia
* Patients with a history of allergy to glycolic acid, poly-L-lactic acid, β-tricalcium phosphate, polyethylene or polydioxane
* Patients who cannot undergo general anesthesia
* Patients who cannot undergo plain X-ray examination or MRI examination
* Patients with previous bone grafting in the shoulder joint
* Patients who participated in another clinical trial within past 3 months
* Patients who are pregnant or lactating. Patients who plan to be pregnant within a year
* Patients judged to be inappropriate for the study by the (sub)investigator

Primary outcomes:
measure: Surgery Success
timeFrame: 12 weeks after surgery
measure: Clinical Function Evaluation
timeFrame: 12 weeks
Secondary outcomes:
measure: Procedure Success
timeFrame: 12 weeks
measure: Clinical Function Evaluation
timeFrame: 24 weeks
measure: Number of Participants With Abnormal Changes in One or More Laboratory Tests
timeFrame: 12 weeks and 24 weeks after surgery
measure: Adverse Event Evaluation
timeFrame: Between the time of obtainment of consent and 24 weeks after surgery
Other outcomes:
Locations:
city: Funabashi-shi
country: Japan
state: Chiba
city: Kobe-shi
country: Japan
state: Hyogo
Study officials:
affiliation: Funabashi Orthopaedic Hospital
name: Hiroyuki Sugaya, MD, Ph.D
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04869319: Electronic Triggers: Messaging After A1C EHR Alert
Official title: Electronic Triggers: Messaging After A1C EHR Alert
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Hemoglobins
Diagnostic Tests
Lead sponsor: NYU Langone Health
Sponsor class: OTHER
First posted: 2021-05-03
Enrollment: 2403
Sex: ALL
Minimum age (years): 18
Maximum age (years): 100
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: MyChart active patients with HbA1C tests \>10 and no follow-up test within 6 months and no appointments scheduled in the next 60 days from data run date

Brief summary: Studying subjects with HbA1C tests \>10 and no follow-up test within 6 months and appointments scheduled in the next 60 days from data run date. Subjects who receive intervention message may be more likely to follow up with their provider to schedule a follow up HbA1C test.


Eligibility criteria: Inclusion Criteria:

* MyChart active patients with HbA1C tests \>10 and no follow-up test within 6 months and no appointments scheduled in the next 60 days from data run date

Exclusion Criteria:

* Patients with a scheduled appointment within 60 days from time algorithm is run; hospital encounters; non English or Spanish patients as indicated by primary language in Epic

Primary outcomes:
measure: Rate of follow up A1C within 9 months after original A1C (allowing 3 months after email is sent)
timeFrame: 2 years
Secondary outcomes:
Other outcomes:
Locations:
city: New York
country: United States
facility: NYU Langone Health
state: New York
Study officials:
References:
Clinical trial NCT04064619: Compare Sudden Stopping and Weaning of Anticholinergics in Recurrence of OAB Symptoms
Official title: Recurrence of Symptoms of Overactive Bladder After Weaning Versus Sudden Stopping of Anticholinergics
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Voiding Disorders
Keywords: OAB
Lead sponsor: Beni-Suef University
Sponsor class: OTHER
First posted: 2019-08-22
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: 60 patients with idiopathic OAB and treated with solifenacin 5mg twice daily for one month. After improvement of their condition, we divided the responders into 2 groups, group I stopped the drug suddenly, while group II underwent gradual weaning of the drug.
Primary purpose: TREATMENT

Brief summary: Our study included 60 patients with idiopathic OAB and treated with solifenacin 5mg twice daily for one month. After improvement of their condition, we divided the responders into 2 groups, group I stopped the drug suddenly, while group II underwent gradual weaning of the drug.

Detailed description: We started an open-label, prospective, two-arm, randomized controlled trial at Beni-Suef University, from January 2018 to January 2019, including 60 patients suffering from OAB symptoms. Patients were recently diagnosed with idiopathic OAB which was not treated prior to enrollment. All participants signed written informed consents. The study protocol was approved by the ethics committee of our faculty. Patients were allocated into 2 equal groups (30 patients in each group) according to a computer-generated random numeric table after exclusion of those who are not eligible or refused to be included in the study

Eligibility criteria: Inclusion Criteria:

* OAB patients.
* Recently diagnosed.

Exclusion Criteria:

* Previous trials of treatment
* UTI, stones, tumors, or Infravesical obstruction.

Primary outcomes:
measure: improvement
timeFrame: 1 month
Secondary outcomes:
measure: recurrence of symptoms
timeFrame: 3 months
Other outcomes:
Locations:
city: Banī Suwayf
country: Egypt
facility: Beni-Suef University
state: Beni-Suef
Study officials:
affiliation: Beni-Suef University
name: Ahmed Abdelbary, MD
role: PRINCIPAL_INVESTIGATOR
References: